Vectus Biosystems Limited
ASX:VBS.AX
0.08 (AUD) • At close September 11, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Vectus Biosystems Limited |
Symbool | VBS.AX |
Munteenheid | AUD |
Prijs | 0.08 |
Beurswaarde | 4,256,840 |
Dividendpercentage | 0% |
52-weken bereik | 0.076 - 0.37 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Karen Annette Duggan |
Website | https://www.vectusbiosystems.com.au |
An error occurred while fetching data.
Over Vectus Biosystems Limited
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)